OncoMatch/Clinical Trials/NCT06975293
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
Is NCT06975293 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies STC-15 in combination with toripalimab for metastatic non-small cell lung cancer.
Treatment: STC-15 in combination with toripalimab — This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 \[PD-1\]) in four different locally advanced unresectable or metastatic tumors such as indications: (1) in combination with toripalimab (anti- programmed cell death 1 \[PD-1\]) in locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC), (2) in combination with toripalimab in locally advanced unresectable or metastatic melanoma, (3) in combination with toripalimab in locally advanced unresectable or metastatic endometrial cancers, and (4) in combination with toripalimab in locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC). This study comprises of 2 parts: a combination dose escalation part (Phase 1b) followed by an assessment of the combination treatment's antitumor activity (Phase 2). This study will be conducted in adult participants with advanced malignancies to characterize the safety, tolerability, PK, and clinical activity of STC-15 in combination with toripalimab.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Melanoma
Endometrial Cancer
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1/PD-L1 therapy — alone or in combination with chemotherapy
must include at least a prior anti-PD-1/L1 alone or in combination with chemotherapy; must have disease progression on prior anti-PD-1/L1
Cannot have received: systemic anticancer therapy
Exception: within 4 weeks prior to first IMP administration
Received prior systemic anticancer therapy including investigational agents within 4 weeks prior to first IMP administration
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Northwell Health Cancer Institute · Lake Success, New York
- The START Center · San Antonio, Texas
- NEXT Oncology · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify